Table 4.
Comparison with the MonarchE Study.
| Present Study (n = 152) | MonarchE Study (n = 2,808) | |
|---|---|---|
| Menopausal | ||
| Premenopausal | 75 (49%) | 1,221 (43.5%) |
| Postmenopausal | 77 (51%) | 1,587 (56.5%) |
| Chemotherapy | ||
| Yes | 127 (84%) | 2,681 (95.5%) |
| (Neoadjuvant) | 47 (31%) | 1,039 (37.0%) |
| (Postoperative) | 80 (53 %) | 1,642 (58.5%) |
| No | 25 (16%) | 127 (4.5%) |
| Types of Chemotherapy | ||
| Anthracyclines and taxane | 106 (70%) | 2,349 (83.7%) |
| Anthracycline only | 3 (2%) | 151 (5.3%) |
| Taxane only | 18 (12%) | 217 (7.7%) |
| Postoperative Endocrine Therapy | ||
| Yes | 150 (99%) | 2,808 (100%) |
| (Tamoxifen) | 76 (50%) | 857 (30.7%) |
| (Anastrozole) | 42 (27%) | 611 (21.9%) |
| (Letrozole) | 28 (18 %) | 1,092 (39.1%) |
| (Exemestane) | 4 (3%) | 225 (8.1%) |
| No | 2 (1%) | 0 |
| LHRH agonist | 15 (10%) | 606 (21.7%) |
| Stage | ||
| Stage ⅠA | 0 | 2 (0.1%) |
| Stage Ⅱ | 58 (38%) | 712 (25.4%) |
| Stage Ⅲ | 94 (62%) | 2,081 (74.5%) |
| Invasive diameter 5 cm or more | 55 (36%) | 610 (21.7%) |
| Lymph node metastasis ≧ 4 | 68 (44%) | 1,680 (59.8%) |
| Ki67 ≧ 20% | 39 (26%) | 953 (34%) |
| Ki67 < 20% | 90 (59%) | 1,855 (66%) |